{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-081307","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2024-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.450189+00:00","generated_at":"2026-05-31T18:27:19.491529+00:00","sec_items":["1.01","3.02","3.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cellectar raises $19.4M via warrant exercise; new warrants could add $73.3M","bullets":["Gross proceeds of ~$19.4M from exercise of Tranche B warrants at reduced price of $2.52/share.","New Tranche A, B, C warrants could generate up to $73.3M additional gross proceeds if exercised.","Tranche A warrants ($2.52 exercise) trigger on FDA assigning PDUFA date for iopofosine I 131.","Tranche B ($4.00) triggers on FDA approval; Tranche C ($5.50) on quarterly revenue >$10M from iopofosine.","Company expects to file NDA for iopofosine I 131 in Q4 2024, seeking priority review."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-081307","json":"https://secwatch.observer/filing/0001104659-24-081307.json","markdown":"https://secwatch.observer/filing/0001104659-24-081307.md","text":"https://secwatch.observer/filing/0001104659-24-081307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924081307/0001104659-24-081307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924081307/tm2419897d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T18:27:19.491529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}